Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.
about
The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An UpdateThe signaling role of CD40 ligand in platelet biology and in platelet component transfusionThe Inflammatory Role of Platelets: Translational Insights from Experimental Studies of Autoimmune DisordersRelease of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusionModeling HIV-1 Induced Neuroinflammation in Mice: Role of Platelets in Mediating Blood-Brain Barrier DysfunctionPlatelet transfusion alters CD40L blood level and release capacity in patients suffering from thrombocytopenia.Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes.Venous thrombosis and prothrombotic factors in inflammatory bowel disease.Antibodies against gonadotropin-releasing hormone (GnRH) and destruction of enteric neurons in 3 patients suffering from gastrointestinal dysfunction.The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease.Etiopathogenesis of inflammatory bowel diseasesInflammatory bowel disease and thromboembolismInterleukin-1beta mediates the extra-intestinal thrombosis associated with experimental colitis.Role of the endothelium in inflammatory bowel diseases.Microvascular thrombosis and CD40/CD40L signaling.Venous and arterial disease in inflammatory bowel disease.Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies.Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signalingBudd-Chiari syndrome in a patient with ulcerative colitis and no inherited coagulopathy.Premature labor: a state of platelet activation?Cardiovascular complications in inflammatory bowel disease.Thrombosis in inflammatory bowel diseases: what's the link?The CD40/CD40L costimulatory pathway in inflammatory bowel diseasePlatelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications.Platelet depletion in mice increases mortality after thermal injury.Platelets at the interface of thrombosis, inflammation, and cancer.Angiogenesis blockade as a new therapeutic approach to experimental colitis.Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.Novel uses for anti-platelet agents as anti-inflammatory drugs.Persistence of high CD40 and CD40L expression after restorative proctocolectomy for ulcerative colitis.Immunogenetics of autoimmune thyroid diseases: A comprehensive review.Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1-mediated neutrophilic acute lung inflammation.Therapy insight: Vascular complications in patients with inflammatory bowel disease.Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease.Stroke in inflammatory bowel disease: a report of two cases and review of the literature.Inflammation and coagulation in inflammatory bowel disease: The clot thickens.Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease?The Serum Levels of the Soluble Factors sCD40L and CXCL1 Are Not Indicative of EndometriosisInterferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever.
P2860
Q26777192-D1A6A3A4-E998-40C2-B626-EC1611E3A190Q26863134-2ED93AA0-3DC5-4896-8580-C2E5036CCBE3Q28071325-39608DBA-CD7E-4A8E-8C71-65BDE36673FDQ28221912-C6381122-6BAE-4DDD-AF4D-9A67A54B5468Q28550869-1DF85D05-4C75-44E3-8D8E-64E13AAFA5B0Q33398221-EA73F588-3A01-45CB-972E-7D4CC154A100Q33509456-E782C615-BD19-41CF-A85F-8C0D6D517BB4Q33564092-3E9A6435-50A6-4486-95CB-C697801892D3Q33582722-9E70F9A8-84DF-47ED-8EED-0E8A157327A4Q33745206-B6C5C4D9-EB57-49F7-B2A2-95957EFCC728Q33866988-E12A871E-F7F1-48DB-9F84-5E90ADC4D0B4Q34326640-C7D12315-EF3B-492C-8F33-3027AEE2EE2BQ34358132-09BB0DD4-2A89-4EB0-8EDB-95AE436FC820Q34579746-2AEDB637-AF2C-4019-B349-21A82FB4B098Q34630514-D55649FE-6EDD-4C4A-B29B-ECA3778B63D1Q34714365-DD92B3AB-D0B7-4B7B-996B-4181092FAC45Q34779205-7627C9AE-B753-4F60-8D02-94B78539CEDAQ35030705-135A92EE-1C9A-4CF8-9275-2D246B02F16EQ35039893-35CE728C-CE5C-4194-99B9-712AF4A76551Q35174822-5B7D62DD-1607-4060-B338-BF03B8F2B744Q35185510-B4EAA1EE-3CFE-41D4-BCAE-C93B2553D877Q35197222-5B4ABEC7-A184-4731-9251-2F85B84DD332Q35368162-D904C7BA-029F-45D7-A3D8-7048FAD4E33FQ35596631-24154617-9F86-46CB-A438-14F4ACFAF171Q35765113-381E397F-C613-43A3-99A9-0D1E30832BA5Q35849695-B584FA8E-B659-4529-B5BF-0EE1457C9A11Q35904932-B99D1DC8-BDD1-49C0-B604-F9E2D5F2DABEQ35953816-C18949C4-A632-4E5F-814B-A5F900A0D9C2Q35994774-D8F8AA6E-259D-4250-84DF-E48AB5AE8CC1Q36171374-D70494AA-D906-41EB-B469-DD43FD2D4102Q36213927-10DD56B4-FE4C-49B8-8F52-8168B99CF7B6Q36236762-C5961088-9B2F-4154-93B6-1516CC89D21FQ36253991-EF762598-6DA6-4F47-A195-36D50DA1416EQ36304138-4D2198C6-01F0-4CA0-8AAB-B8309C26EEE3Q36470212-8DB32A00-C875-474F-A300-1B40FAD16A52Q36580179-493DE078-58C6-466F-8070-FCD6D6F62BACQ36652262-90BC31C5-57F5-412C-8DAF-A0E48D1E64F6Q36804314-EBF3187F-97B8-41B5-9186-25C8AF787299Q36854749-40033C1D-E1D6-4AF3-91F5-7CD0BCC8738DQ36949893-079241B7-454A-4DDE-8F01-2504103734C5
P2860
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Activated platelets are the so ...... matory bowel disease patients.
@ast
Activated platelets are the so ...... matory bowel disease patients.
@en
type
label
Activated platelets are the so ...... matory bowel disease patients.
@ast
Activated platelets are the so ...... matory bowel disease patients.
@en
prefLabel
Activated platelets are the so ...... matory bowel disease patients.
@ast
Activated platelets are the so ...... matory bowel disease patients.
@en
P2093
P2860
P921
P356
P1433
P1476
Activated platelets are the so ...... matory bowel disease patients.
@en
P2093
A Gasbarrini
P2860
P304
P356
10.1136/GUT.52.10.1435
P407
P577
2003-10-01T00:00:00Z